Skip to main content

FDA Updates

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC

Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping

Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations

FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma

Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer

FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications

Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer

Recent Cancer Drugs Approved by the FDA

13
14
15
16
17
18
19

Page 16 of 33
Results 151 - 160 of 330